Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Purdue researcher pursuing treatment for aggressive form of brain cancer

Thursday, September 22, 2022 01:00 PM EDT
By Wes Mills
Sandro Matosevic is an assistant professor in the Department of Industrial and Physical Pharmacy at Purdue (photo courtesy: Purdue)

Indianapolis-based Monon Bioventures LLC has received a one-year, nearly $400,000 grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy. Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord.

“It grows, multiplies and spreads quickly, is almost always lethal, and there is no effective cure. New, effective therapies are desperately needed,” said Sandro Matosevic, assistant professor in the Department of Industrial and Physical Pharmacy, who has developed a potential treatment.

Matosevic’s work demonstrates that human immune “natural killer” (NK) cells can be “armed” to specifically attack glioblastomas.

Monon Bioventures will partner with Matosevic and Genezen Inc., a therapeutics manufacturing lab in Fishers.

“Therapeutics for certain cancers have used related approaches with other immune cells, called T cells, which are obtained from the patient,” said Matosevic said. “Natural killer cells can be accepted from multiple donors, however, not just the patient, which makes them much safer, and which dramatically expands our ability to manufacture them in large doses to treat many patients.”

Matosevic worked with the Purdue Research Foundation Office of Technology Commercialization, which has applied for a patent to protect Matosevic’s intellectual property. The Office has granted Monon Bioventures the option to negotiate a license to the intellectual property.

“His discovery provides a critical preclinical proof of concept of the disease,” said Joe Trebley, president and CEO of Monon Bioventures. “Our plans are to translate that discovery into the clinic by first working on the manufacturability of the novel therapeutic.”

After this work is complete, Trebley says Monon Bioventures will discuss with the U.S. Food and Drug Administration the company’s plan to move the treatment to clinical studies.

Story Continues Below

Most Popular Stories

Perspectives

Strategic steps to take before you sell your company

Strategic steps to take before you sell your company

Before initiating the sale process, it's crucial to evaluate the financial health of your business. Prospective buyers will closely examine financial statements, profit margins, cash flow, and growth potential. Engaging a professional accountant or financial advisor can provide valuable insights to ensure your financial records are accurate and well-organized....

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service